Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Bronchopulmonary Dysplasia
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: Hubert Ballard; Other
Eligibility: Up to 72 Hours
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Nocturia, Daytime Sleepiness
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions: Glutamine, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 1,433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 15
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pamrevlumab, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: armodafinil (Nuvigil), placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Menopause
Interventions: Nitrate-Rich Beetroot Juice, High Intensity Exercise, Moderate Intensity Exercise, Nitrate-Depleted Placebo Beetroot Juice; Dietary Supplement · Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Carcinoma, Hepatocellular
Interventions: Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 23
States / cities: San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 19 more

Conditions: Pre-diabetes
Interventions: epicatechin, Placebo; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 21 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: San Diego, California

Conditions: Pain
Interventions: Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine; Drug
Lead sponsor: Elizabeth Micks; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, Placebo; Drug · Biological
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: New Haven, Connecticut • The Woodlands, Texas

Conditions: Alcoholic Intoxication, Neurobehavioral Manifestations
Interventions: Alcohol, Placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 30 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Biliary Cirrhosis
Interventions: Tetrathiomolybdate, Placebo; Drug · Other
Lead sponsor: George Brewer; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Discogenic Pain
Interventions: High yield pure PRP, Placebo, ProPlaz PPC; Device · Other
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more

Conditions: Pregnancy Related, Breast Feeding, Exclusive
Interventions: Breastfeeding Education; Behavioral
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Intermittent Explosive Disorder
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 9
States / cities: Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Fibromyalgia
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years to 68 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Conditions: Obese, Overweight, Healthy
Interventions: LB64640, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Mild Cognitive Impairment
Interventions: Nicotine Transdermal Patch, Placebo Patch; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 90 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 36
States / cities: Scottsdale, Arizona • North Little Rock, Arkansas • Downey, California + 31 more

Conditions: Tobacco Smoking
Interventions: Ketamine, Midazolam, Dexmedetomidine, Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Opioid Sensitivity, Individual Difference, Abuse Opioids
Interventions: Within-subject test of blinded study medication; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lower Back Pain Chronic
Interventions: peripheral magnetic stimulation, Home exercise; Device · Behavioral
Lead sponsor: Joe X. Zhang; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Edwards Air Force Base, California

Conditions: Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions: L-citrulline, Plasmalyte A; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: Up to 18 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Pain
Interventions: Lidocaine, Saline; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 4 Years to 10 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Trial II of Lung Protection With Azithromycin in the Preterm Infant

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)

Hydrocodone For Pain Control in First Trimester Surgical Abortion

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Residual Effects of Intoxication on Student Performance

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Safety and Efficacy of PRP for Treatment of Disc Pain

Impact of Lactation Antenatal Teaching by Clinicians and Healthcare Providers

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

The Effect of Milnacipran in Patients With Fibromyalgia

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

Memory Improvement Through Nicotine Dosing (MIND) Study

The Effects of Sedatives on Tobacco Use Disorder Version 2

A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

Trial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain.

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Intravenous Lidocaine for Post-Tonsillectomy Pain in Pediatric Patients